Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$11.35 - $16.73 $106,973 - $157,680
9,425 Added 598.41%
11,000 $162,000
Q4 2023

Feb 14, 2024

BUY
$5.77 - $12.19 $9,087 - $19,199
1,575 New
1,575 $18,000
Q2 2023

Aug 14, 2023

BUY
$6.63 - $9.9 $283,810 - $423,789
42,807 New
42,807 $336,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $709M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Centiva Capital, LP Portfolio

Follow Centiva Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.